The first worldwide study on the treatment with High Intensity Focused Ultrasound of insufficient superficial and perforating veins of the lower limb will be presented
Alfred Obermayer, M.D., vascular surgeon at the St. Joseph Hospital in Vienna, director of the Karl Landsteiner Institute for Functional Phlebology – Melk, Austria and lead investigator, will discuss the trial
Malakoff - FRANCE, November 06, 2017 - THERACLION (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it will host a conference call and webinar to discuss the trial, “Minimally Invasive Treatment of Insufficient Superficial and Perforating Veins of the Lower Limb using HIFU: A single Center Prospective Study - Archimedes 01” The primary objective of the trial is to determine the efficacy, safety, including ease of use and subject tolerability, of the current Echopulse® system using extra corporeal HIFU (also known as High Intensity Focused Ultrasound) delivery in targeted tissues.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer